Nina Reschke
Head of Biology, Senior Director Bright Peak Therapeutics
Seminars
Monday 4th May 2026
Panel Discussion: Building a General Consensus on Model Selection Criteria Across Oncology Drug Development
3:00 pm
- Understanding the different tumour models used in drug discovery and development across the field
- Exploring the various questions and contexts of use for each main model type
- How did you overcome hurdles encountered with your model when trying to better understand your drug/target?
Monday 4th May 2026
Engineering & Validating Next‑Generation Immuno-Cytokines Through Robust & Predictive Preclinical Tumour Models
11:15 am
- Developing first and best in class cytokines with enhanced biological activity using a site-specific chemical conjugation approach
- Navigating the complexity of choosing appropriate tumour models to assess efficacy—including limitations of PDX/CDX, immune deficient systems, and the need for models that accurately recapitulate cytokine–immune cell interactions and tissue specific targeting
- Dissecting the mechanism of action of these molecules using the right tumour model
